根据证监会《上市公司独立董事管理办法》《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运 作》等要求，浙江本立科技股份有限公司（以下简称"公司"）董事会， 就公司现任独立董事王宝庆先生、周华俐女士、赵新建先生的 2024 年度独立性 情况进行评估并出具如下专项意见： 经核查独立董事王宝庆先生、周华俐女士、赵新建先生的任职经历以及签署 的相关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公 司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他 可能妨碍其进行独立客观判断的关系，因此，公司独立董事符合《上市公司独立 董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》等相关法律法规中对独立董事独立性的相关要求。 浙江本立科技股份有限公司 董事会关于独立董事 2024 年度独立性自查情况的专项报告 浙江本立科技股份有限公司 董事会 2025 年 4 月 22 日 ...

浙江本立科技股份有限公司 2024 年度独立董事述职报告 （王宝庆） 本人王宝庆，作为浙江本立科技股份有限公司（以下简称"公司"）的独立 董事，在 2024 年度严格按照《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相 关法律法规、规范性文件及《浙江本立科技股份有限公司章程》的规定和要求履 行独立董事的职务，认真行使公司所赋予的权利，及时了解公司的生产经营信息， 全面关注公司的发展状况，积极出席公司 2024 年度召开的相关会议，对公司董 事会审议的相关事项发表了独立客观的意见，忠实履行职责，充分发挥独立董事 的独立作用，维护了公司、全体股东尤其是中小股东的合法权益。现将 2024 年 度本人履行工作的情况汇报如下： 一、独立董事的基本情况 （一）独立董事工作履历 本人王宝庆，1964 年 5 月出生，中国国籍，无境外永久居留权，经济学硕士 （会计专业），浙江工商大学教授、硕士生导师。1996 年 9 月至 2024 年 5 月任 浙江工商大学教师、教授；2019 ...

Financial Performance - The company's operating revenue for 2024 was ¥708,834,125.46, representing a 1.57% increase compared to ¥697,893,051.87 in 2023[21]. - Net profit attributable to shareholders for 2024 was ¥64,571,985.96, an increase of 8.31% from ¥59,615,904.53 in 2023[21]. - The net profit after deducting non-recurring gains and losses was ¥61,440,085.63, up 9.02% from ¥56,354,683.13 in 2023[21]. - Cash flow from operating activities significantly increased by 156.81% to ¥236,060,400.80 from ¥91,921,049.09 in 2023[21]. - The total assets at the end of 2024 reached ¥1,619,459,478.19, an 8.58% increase from ¥1,491,487,005.16 at the end of 2023[21]. - The company reported a basic earnings per share of ¥0.62 for 2024, a 10.71% increase from ¥0.56 in 2023[21]. - The total net profit for the company after deducting non-recurring gains and losses was ¥3,131,900.33 in 2024, slightly down from ¥3,261,221.40 in 2023[27]. - The company's total revenue for the reporting period was 657,666,703.25 CNY, with a year-on-year increase of 0.98%[60]. - The gross profit margin for the pharmaceutical intermediates segment was 16.08%, reflecting a slight increase of 0.10% compared to the previous year[60]. Dividend Distribution - The company plans to distribute a cash dividend of 2.00 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[4]. - The company plans to distribute cash dividends of RMB 2.00 per 10 shares, totaling RMB 20,634,527.60 (including tax), with a distribution ratio of 100% of the profit distribution total[153]. - The total number of shares for the cash dividend distribution is based on 103,172,638 shares, excluding 2,847,362 shares held in the repurchase account[154]. - The company has repurchased 2,847,362 shares at a total cost of RMB 50,002,854.65 (excluding transaction fees), with the total cash dividend and share repurchase amounting to RMB 70,637,382.25, representing 109.39% of the net profit attributable to shareholders for the fiscal year 2024[154]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements in the annual report[4]. - The company's management discusses potential risks and countermeasures in the section on future development outlook[4]. - The company is committed to optimizing internal controls and risk management, enhancing overall business management levels through independent audits and supervision[56]. - The company recognizes risks from macroeconomic fluctuations and will adapt its strategies to mitigate potential impacts on business operations[109]. Technological Innovation - The company has established three major technology platforms for synthetic technology[15]. - The company is focusing on technological innovation and supply chain restructuring to capitalize on structural opportunities in the quinolone intermediate industry[32]. - The company is actively pursuing new product development through its three major technology platforms, including carbonylation and continuous flow reaction technologies[48]. - The company is committed to increasing R&D investment and technical reserves to enhance its core technology development and accumulation, aiming to maintain a technological leadership advantage[187]. Environmental Responsibility - The company emphasizes clean production processes and has implemented measures to minimize environmental impact[167]. - The company has established a comprehensive environmental risk emergency mechanism, with a plan effective for three years[168]. - The company conducts regular environmental self-monitoring and engages qualified testing units for periodic assessments[169]. - The company reported a total nitrogen discharge of 3.613 tons, well below the regulatory limit of 70 mg/L[166]. - The company reported a sulfur dioxide emission of 0.54 tons, significantly lower than the allowable limit of 200 mg/m³[166]. - The company's environmental protection expenditure amounted to RMB 22.4265 million, including costs for waste disposal and maintenance of environmental facilities[170]. Governance and Compliance - The company has established a comprehensive governance structure with a board of directors, supervisory board, and management team, ensuring independent operations[120]. - The board of directors consists of 7 members, including 3 independent directors, ensuring diverse expertise and independent decision-making[116]. - The company strictly adheres to information disclosure obligations, ensuring that all investors have equal access to information, thereby protecting the rights of minority investors[118]. - The company has implemented a comprehensive internal control system to ensure accurate financial reporting[161]. - The audit committee has conducted thorough internal audits and found no issues during the reporting period[145]. Market Expansion and Sales - The company expanded its international market, with foreign sales reaching 188.58 million CNY, a 17.88% increase from the previous year[58]. - The pharmaceutical intermediates segment contributed 657.67 million CNY, accounting for 92.78% of total revenue, with a year-on-year growth of 0.98%[58]. - The company increased its direct sales model revenue to 591.74 million CNY, representing 83.48% of total revenue, with a significant growth of 20.87%[58]. - The company is positioned to support high-quality and green development in the pesticide industry, aligning with national policies[34]. Employee Management - The total number of employees at the end of the reporting period is 489, with 473 in the parent company and 16 in major subsidiaries[146]. - The company has established a comprehensive human resources management system to protect employee rights and promote talent development[174]. - The company implements a differentiated salary system based on job responsibilities, performance, and individual capabilities[148]. - The company is committed to continuously improving the performance evaluation mechanism to enhance employee skills and work efficiency[148]. Financial Management - The company has a total of ¥7,392,000.00 in cash as guarantee deposits, indicating a commitment to secure financial obligations[86]. - The company has not engaged in any securities or derivative investments during the reporting period[88][89]. - The company has committed to invest in projects with a total fundraising amount of 14.3 million yuan, with a completion rate of 50.2% as of the report date[93]. - The company has not reported any significant accounting policy changes or errors during the reporting period[194]. Shareholder Relations - The company actively engages with shareholders, providing opportunities for participation in decision-making processes[116]. - The company will ensure compliance with relevant laws and regulations regarding shareholder rights and related transactions[184]. - The company will publicly explain any failure to fulfill commitments in the prospectus on designated websites if such failures occur[189]. - The company has 20 shareholders, including 18 natural persons and 2 partnership enterprises, and has disclosed shareholder information accurately and completely in the prospectus[189].

Financial Performance - The company's revenue for Q1 2025 was ¥161,979,567.81, a decrease of 13.95% compared to ¥188,234,413.52 in the same period last year[5] - Net profit attributable to shareholders was ¥15,246,208.73, down 8.07% from ¥16,585,417.53 year-on-year[5] - The company's basic earnings per share were ¥0.15, down 6.25% from ¥0.16 in the same period last year[5] - Total operating revenue for the current period is ¥161,979,567.81, down 13.9% from ¥188,234,413.52 in the previous period[21] - Net profit for the current period is ¥15,246,208.73, representing a decline of 8.1% from ¥16,585,417.53 in the previous period[22] Cash Flow and Liquidity - The net cash flow from operating activities was -¥54,354,394.96, a significant decline of 180.15% compared to ¥67,819,416.75 in the previous year[5] - Operating cash flow net amount is -¥54,354,394.96, a significant decrease from ¥67,819,416.75 in the previous period[24] - Cash and cash equivalents at the end of the period stand at ¥465,728,960.50, down from ¥583,772,301.99 at the end of the previous period[25] - The net cash flow from investing activities is -¥26,709,405.34, worsening from -¥14,635,453.88 in the previous period[24] - The net cash flow from financing activities was ¥10,588,644.50, a turnaround from -¥32,412,744.57 in the same period last year, mainly due to last year's share buyback[12] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,600,283,417.29, a decrease of 1.18% from ¥1,619,459,478.19 at the end of the previous year[5] - Current assets totaled CNY 939,597,095.82, a slight decrease from CNY 957,860,811.86, indicating a reduction of about 1.93%[18] - The company's cash and cash equivalents decreased to CNY 473,130,960.50 from CNY 542,933,486.22, reflecting a decline of approximately 12.87%[18] - Total liabilities decreased to CNY 281,965,078.98 from CNY 317,364,215.16, representing a reduction of about 11.09%[19] - The company's equity increased to CNY 1,318,318,338.31, up from CNY 1,302,095,263.03, indicating an increase of approximately 1.24%[19] Operational Metrics - The company reported a significant increase in sales expenses by 103.13% to ¥670,322.50, attributed to an increase in sales personnel and employee compensation[10] - Research and development expenses increased to ¥6,049,117.57, up from ¥5,461,819.93 in the previous period, indicating a focus on innovation[21] - Accounts receivable financing increased by 136.25% to ¥79,356,759.24 due to a reduction in bank acceptance bill endorsements[8] - Prepayments surged by 387.82% to ¥3,480,424.55, primarily due to increased advance payments for raw materials[8] - Accounts receivable increased to CNY 157,870,686.25 from CNY 142,855,428.03, marking an increase of about 10.51%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,355[13] - The company has a total of 2,847,362 shares held in the repurchase account, accounting for 2.69% of the total shares[15]

■■■■■301065■■■■2025■■■■■■■■■1.62■■■■■■■13.95%■■■■1524.62■■■■■■■8.07%■ ...

证券代码：301065 证券简称：本立科技 公告编号：2025-004 浙江本立科技股份有限公司 第四届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江本立科技股份有限公司（以下简称"公司"）第四届监事会第五 次会议于 2025 年 3 月 28 日在公司三楼会议室以现场的方式召开。本次会 议通知已于 2025 年 3 月 22 日以邮件方式向公司全体监事发出。本次会议 由公司监事会主席钱沛良先生主持,会议应到监事 3 人，实到监事 3 人，公 司部分高级管理人员列席会议。会议的召集、召开和表决程序符合《公司 法》和《公司章程》的有关规定，形成的决议合法有效。 二、监事会会议审议情况 经与会监事认真审议，形成以下决议： （一）审议通过了《关于部分募集资金投资项目延期的议案》 经审核，监事会认为：公司本次部分募投项目延期，不存在改变或变 相改变募集资金投资项目的投资方向和项目的建设内容，不存在损害公司 及股东利益的情形，符合公司的实际情况和发展战略。因此，同意公司本 次对部分募投项目进行延期的事项。 具体内容 ...

证券代码：301065 证券简称：本立科技 公告编号：2025-005 浙江本立科技股份有限公司 关于部分募集资金投资项目延期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 浙江本立科技股份有限公司（以下简称"公司"）于 2025 年 3 月 28 日召 开第四届董事会第五次会议和第四届监事会第五次会议，审议通过了《关于部 分募集资金投资项目延期的议案》，同意公司将募集资金投资项目"基于 CO 羰 基化反应的丙烯酸酯类产品技改及新建 2,4-二氯-5-氟苯甲酰氯项目"中的 DDTA 技改新增 500 吨项目达到预计可使用状态日期由 2025 年 3 月 31 日延长至 2025 年 6 月 30 日。保荐机构长城证券股份有限公司对本事项出具了明确无异 议的核查意见。 根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要 求》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运 作》等相关规定，本次募投项目延期事项在董事会审批权限范围内，无需提交 公司股东会审议。现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理 ...

长城证券股份有限公司 关于浙江本立科技股份有限公司 部分募集资金投资项目延期的核查意见 长城证券股份有限公司（以下简称"长城证券"或"保荐机构"）作为浙江 本立科技股份有限公司（以下简称"本立科技"或"公司"）首次公开发行股票 并在创业板上市之保荐机构，根据《证券发行上市保荐业务管理办法》《上市公 司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》《深圳证券交易 所创业板股票上市规则（2024 年修订）》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等相关规定，长城证券对本立科技部分 募集资金投资项目延期事项进行了核查，核查的具体情况如下： 一、募集资金基本情况 注：上述累计投入金额未经审计。 三、本次部分募投项目延期的情况及原因 经中国证券监督管理委员会《关于同意浙江本立科技股份有限公司首次公开 发行股票注册的批复》（证监许可[2021]2601 号）同意，公司获准向社会公开发 行人民币普通股（A 股）股票 17,680,000 股，每股面值 1 元，每股发行价格为人 民币 42.50 元，募集资金总额为人民币 751,400,000.00 元，扣除发行费用总额 68 ...

证券代码：301065 证券简称：本立科技 公告编号：2025-003 浙江本立科技股份有限公司 第四届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江本立科技股份有限公司（以下简称"公司"）第四届董事会第五 次会议于 2025 年 3 月 28 日在公司三楼会议室以现场结合通讯的方式召开。 本次会议通知已于 2025 年 3 月 22 日以邮件方式向公司全体董事发出。本 次会议由公司董事长吴政杰先生主持,会议应到董事 7 人，实到董事 7 人， 公司监事、高级管理人员列席会议。会议的召集、召开和表决程序符合《公 司法》和《公司章程》等相关法律法规、规章及其他规范性文件的规定， 形成的决议合法有效。 二、董事会会议审议情况 经与会董事认真审议，形成以下决议： （一）审议通过了《关于部分募集资金投资项目延期的议案》 董事会同意公司将"基于 CO 羰基化反应的丙烯酸酯类产品技改及新建 2,4-二氯-5-氟苯甲酰氯项目"中的 DDTA 技改新增 500 吨项目达到预计可 使用状态日期由 2025 年 3 月 31 ...

证券代码：301065 证券简称：本立科技 公告编号：2025-002 浙江本立科技股份有限公司 一、本次回购股份的实施情况 1、2024年2月20日，公司通过股份回购专用证券账户以集中竞价交易方式首次 回购公司股份，回购数量为308,657股，占公司当时总股本的0.29%。具体内容详 见公司于2024年2月21日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关 于首次回购公司股份的公告》（公告编号：2024-007）。 2、截至2024年3月22日，公司通过股份回购专用证券账户以集中竞价交易的方 式累计回购公司股份1,121,212股，占公司当时总股本的1.06%。具体内容详见公司 于2024年3月26日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于回购 公司股份比例达1%暨回购股份进展的公告》（公告编号：2024-009）。 3、截至2024年3月27日，公司通过股份回购专用证券账户以集中竞价交易的方 式累计回购公司股份2,375,812股，占公司当时总股本的2.24%。具体内容详见公司 于2024年3月29日在巨潮资讯网（http://www.cn ...